AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 MAR 4 - (NewsRx.com & NewsRx.net) -- VIVU.S., Inc., (VVU.S.) announced data on TA-1790, its oral phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED).
The phase II head-to-head at-home study comparing the onset of action between TA-1790 and Pfizer's (PFE) Viagra (sildenafil) showed comparable results. With each product, subjects had erections sufficient to achieve vaginal penetration on approximately 80% of attempts. These successful attempts occurred, on average, within 20 minutes after dosing.
This double-blind, randomized, crossover study in the home setting provides additional data to complement the earlier trial in the clinical setting (the in-clinic RigiScan efficacy trial results announced June 2003).
The efficacy demonstrated by TA-1790 in this at-home trial continues to support the rapid absorption and onset of action seen in the earlier in-clinic trial; however, it did not out-perform Viagra as it did in the in-clinic study.
"TA-1790's onset of action was consistently strong in both the at-home and in-clinic studies," said John Dietrich, PhD vice president of research and development for VIVU.S.
"These data and our belief in the overall safety profile of TA-1790 support our plans to continue the TA-1790 clinical development ...
Source: HighBeam Research, Results announced for TA-1790 phase II head-to-head study with Viagra.